

**MAIL STOP PATENT APP**  
Attorney Docket: 25350  
**PRELIMINARY AMENDMENT**

**ATTACHMENT A**

In the claims:

1. (Original) Use of a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5 for the preparation of a iontophoretic device for the treatment of Parkinson's disease.
2. (Original) Use according to claim 1, wherein the concentration of rotigotine is at least 0.5 mg/ml.
3. (Currently Amended) Use according to Claim 1, ~~any one of claims 1 or 2,~~ wherein the concentration of rotigotine is 0.5 to 3 mg/ml.
4. (Currently Amended) Use according to Claim 1, ~~any one of claims 1 to 3,~~ wherein the chloride salt is selected from NaCl, triethylammonium chloride and tributylammonium chloride.
5. (Original) Use according to claim 4, wherein the chloride salt is triethylammonium chloride or tributylammonium chloride.
6. (Currently Amended) Use according to Claim 1, ~~any one of claims 1 to 5,~~ wherein the concentration of the chloride salt is 60 to 80 mmol/l.
7. (Currently Amended) Use according to Claim 1 ~~any one of claims 1 to 6,~~ wherein the composition is used in the donor phase of the iontophoretic device.
8. (Currently Amended) Use according to Claim 1, ~~any one of~~

~~claims 1 to 7~~, wherein the composition in the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/l, wherein the pH of the donor phase is 4.5 to 5.5.

9. (Original) A method for the treatment of Parkinson's disease characterised by applying a iontophoretic device, which comprises a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5, onto the skin of a patient in need thereof.
10. (New) Use according to Claim 2, ~~any one of claims 1 or 2~~, wherein the concentration of rotigotine is 0.5 to 3 mg/ml.
11. (New) Use according to Claim 2, ~~any one of claims 1 to 7~~, wherein the composition in the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/l, wherein the pH of the donor phase is 4.5 to 5.5.
12. (New) Use according to Claim 3, ~~any one of claims 1 to 7~~, wherein the composition in the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/l, wherein the pH of the donor phase is 4.5 to 5.5.
13. (New) Use according to Claim 4, ~~any one of claims 1 to 7~~, wherein the composition in the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/l, wherein the pH of the donor phase is 4.5 to 5.5.

14. (New) Use according to Claim 5, ~~any one of claims 1 to 7~~, wherein the composition in the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/l, wherein the pH of the donor phase is 4.5 to 5.5.
15. (New) Use according to Claim 6, ~~any one of claims 1 to 7~~, wherein the composition in the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/l, wherein the pH of the donor phase is 4.5 to 5.5.
16. (New) Use according to Claim 7, ~~any one of claims 1 to 7~~, wherein the composition in the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/l, wherein the pH of the donor phase is 4.5 to 5.5.